Completed NA INTERVENTIONAL 1-arm NCT00457938

Novel Therapies for Metabolic Complications of Lipodystrophies

Novel Therapies for Metabolic Complications in Patients With Lipodystrophies

Sponsor: Amylin Pharmaceuticals, LLC.

Conditions Diabetes Hepatic Steatosis Hypertriglyceridemia Insulin Resistance

Interventions Diet low-fat diet ( Still recruiting )

Updated 7 times since 2017 Last updated: Oct 11, 2018 Started: Apr 30, 2006 Primary completion: Nov 30, 2014 Completion: Nov 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Diabetes and Hepatic Steatosis and is currently completed. Amylin Pharmaceuticals, LLC. leads this study, which shows 7 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Nov 2018 — Jan 2021 [monthly]

Completed NA

Status: Unknown Status → Completed · Phase: PHASE2_PHASE3 → NA
Jun 2018 — Nov 2018 [monthly]

Unknown Status PHASE2_PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Unknown Status PHASE2_PHASE3
Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE2_PHASE3

First recorded

Apr 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amylin Pharmaceuticals, LLC.
National Institutes of Health (NIH)
Takeda
University of Texas Southwestern Medical Center

Data source: University of Texas Southwestern Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Dallas, United States